Comparing adalimumab and infliximab in the prevention of postoperative recurrence of Crohn's disease: a systematic review and meta-analysis Article (Faculty180)

cited authors

  • Gangwani, Manesh K; Nawras, Mohamad; Aziz, Muhammad; Rani, Anooja; Priyanka, Fnu; Dahiya, Du S; Ahmed, Zohaib; Sohail, Amir H; Karna, Rahul; Lee-Smith, Wade; Kamal, Faisal; Kobeissy, Abdallah; Alastal, Yaseen

description

  • Crohn's disease is a relapsing disease that often requires operative management. Prevention of postoperative recurrence (POR) is critical to maintain remissions. Biologic agents have proven to be most successful in remission maintenance. We made a direct head-to-head comparison of the 2 anti-tumor necrosis factor agents, infliximab (IFX) and adalimumab (ADA), to compare endoscopic and clinical POR of Crohn's disease.

authors

publication date

  • 2023

published in

start page

  • 293

end page

  • 299

volume

  • 36